PTC Inc. (NASDAQ:PTC) is among the most profitable software stocks to buy now. On February 9, TheFly reported that BofA reduced its price target on PTC Inc. (NASDAQ:PTC) to $172, down from $190, and ...

This verdict could spell the end for Translarna’s decades-long and tumultuous US DMD development journey.

PTC Therapeutics has withdrawn its New Drug Application resubmission for Translarna following feedback from the US Food and Drug Administration. Translarna is an investigational therapy for nonsense ...

With the writing apparently on the wall, PTC Therapeutics has called off its latest bid for FDA approval of its Duchenne muscular dystrophy (DMD) drug Translarna.  | Late Thursday, PTC revealed that ...

PTC Therapeutics announced it will withdraw the ataluren NDA for nmDMD, citing FDA concerns regarding the evidence of the agent's effectiveness.

In a statement, PTC's chief executive, Matthew Klein, said the company had decided to pull the filing for Translarna (ataluren) as a treatment for nonsense mutation DMD after the FDA said it was ...

Enables faster, more collaborative product execution with a cloud-based PLM solution built to support future growth BOSTON, ...

PTC repurchased $200 million in common stock during Q1 and plans to increase buybacks to $250 million in Q2, targeting a ...

Investing.com -- PTC Inc (NASDAQ:PTC) stock fell 3.8% on Thursday after Google announced a major upgrade to its Gemini 3 Deep ...

Honorees recognized at PTC’s largest annual conference in its 48 year history Each recipient is contributing in ...

PTC Therapeutics withdrew its New Drug Application (NDA) resubmission for Translarna (ataluren) in nonsense mutation Duchenne muscular dystrophy (nmDMD) following feedback from FDA indicating that the ...

Wall Street expects a year-over-year increase in earnings on higher revenues when PTC Therapeutics (PTCT) reports results for ...